PubRank

P Valent

Author PubWeight™ 194.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991 2.50
2 Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2008 2.44
3 Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003 2.08
4 Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991 1.62
5 Basophils are not the key antigen-presenting cells in allergic patients. Allergy 2012 1.57
6 Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012 1.57
7 Prevention of latex allergy by selection of low-allergen gloves. Clin Exp Allergy 2000 1.55
8 Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004 1.53
9 Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2010 1.48
10 Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001 1.48
11 Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med 1997 1.44
12 A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol 2002 1.44
13 Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004 1.43
14 Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2009 1.43
15 Effects of dental amalgam and its components of histamine release from human basophils and tissue mast cells. Wien Klin Wochenschr 1998 1.39
16 Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005 1.38
17 Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992 1.35
18 Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009 1.32
19 Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998 1.28
20 Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012 1.27
21 Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2009 1.22
22 Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997 1.22
23 Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001 1.21
24 Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001 1.17
25 Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999 1.17
26 Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000 1.16
27 Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006 1.16
28 Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994 1.15
29 Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy 2006 1.14
30 Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001 1.13
31 The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood 1994 1.12
32 Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007 1.11
33 Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology 1996 1.09
34 Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest 2008 1.08
35 Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001 1.08
36 The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999 1.08
37 cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. J Immunol 1993 1.07
38 Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004 1.06
39 Molecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen. J Immunol 2001 1.06
40 CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol 2007 1.05
41 Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000 1.05
42 Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol 1995 1.05
43 A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain. J Immunol 2000 1.04
44 Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998 1.03
45 Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 1998 1.03
46 Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol 1993 1.03
47 Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004 1.02
48 Characterization of Der p 21, a new important allergen derived from the gut of house dust mites. Allergy 2008 1.01
49 Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J Invest Dermatol 1998 1.00
50 Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. Eur J Cancer 2011 1.00
51 The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood 2001 1.00
52 Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008 0.99
53 Cigarette smoke facilitates allergen penetration across respiratory epithelium. Allergy 2008 0.99
54 The experience of a mental health team involved in the early phase of a disaster. Aust N Z J Psychiatry 1984 0.99
55 Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004 0.98
56 IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 1991 0.98
57 Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001 0.98
58 Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol 2008 0.98
59 Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001 0.98
60 Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res 2001 0.97
61 Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J 1998 0.97
62 Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001 0.96
63 Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994 0.96
64 Molecular characterization of dog albumin as a cross-reactive allergen. J Allergy Clin Immunol 1994 0.96
65 Identification of common allergenic structures in hazel pollen and hazelnuts: a possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. J Allergy Clin Immunol 1992 0.95
66 Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol 1998 0.95
67 Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy 2012 0.95
68 Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001 0.95
69 B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999 0.95
70 Identification of common allergenic structures in mugwort and ragweed pollen. J Allergy Clin Immunol 1998 0.95
71 Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy 2009 0.94
72 Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007 0.94
73 A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia 2009 0.94
74 Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994 0.93
75 Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994 0.93
76 Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998 0.93
77 Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). J Allergy Clin Immunol 1996 0.93
78 Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Eur J Clin Invest 2004 0.93
79 Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol 1996 0.93
80 Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen. J Immunol 1999 0.92
81 Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy 2012 0.92
82 A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol 1998 0.92
83 Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol 1998 0.92
84 Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study. J Clin Pathol 2003 0.92
85 Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009 0.91
86 CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 2007 0.90
87 Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens. J Clin Pathol 2003 0.90
88 Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis. Leukemia 1998 0.90
89 Induced gene expression of the hypusine-containing protein eukaryotic initiation factor 5A in activated human T lymphocytes. Proc Natl Acad Sci U S A 1994 0.90
90 Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 2001 0.90
91 The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost 2006 0.90
92 Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998 0.90
93 Response of L-929 fibroblasts, human gingival fibroblasts, and human tissue mast cells to various metal cations. J Dent Res 1995 0.89
94 Differential expression of cell surface integrins on human mast cells and human basophils. Ann Hematol 1992 0.89
95 Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 2013 0.89
96 Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology 2010 0.89
97 Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol 2006 0.88
98 Interleukin-3 promotes the expression of E-NPP3/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy. Int J Immunopathol Pharmacol 2007 0.88
99 Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp Hematol 1991 0.88
100 Type beta transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils. Blood 1992 0.88
101 Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. Genes Chromosomes Cancer 2000 0.88
102 The surface membrane antigen phenotype of human blood basophils. Allergy 1994 0.88
103 Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 2009 0.88
104 Metal ion-induced toxic histamine release from human basophils and mast cells. J Biomed Mater Res 1998 0.88
105 Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995 0.87
106 IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease. Clin Exp Immunol 1999 0.87
107 In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006 0.87
108 The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood 1989 0.87
109 IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases. Clin Exp Immunol 2002 0.87
110 Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009 0.87
111 The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood 1997 0.87
112 Hymenoptera-venom-induced upregulation of the basophil activation marker ecto-nucleotide pyrophosphatase/phosphodiesterase 3 in sensitized individuals. Int Arch Allergy Immunol 2001 0.87
113 Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest 2008 0.87
114 The immunoglobulin-like modules Cepsilon3 and alpha2 are the minimal units necessary for human IgE-FcepsilonRI interaction. J Clin Invest 1999 0.86
115 The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells. Curr Cancer Drug Targets 2012 0.86
116 Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I. J Biol Chem 1993 0.86
117 An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 2006 0.86
118 Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum 2000 0.86
119 Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008 0.86
120 Gastro-duodenal digestion products of the major peanut allergen Ara h 1 retain an allergenic potential. Clin Exp Allergy 2006 0.86
121 Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. Exp Hematol 1993 0.86
122 Purification, biochemical, and immunological characterisation of a major food allergen: different immunoglobulin E recognition of the apo- and calcium-bound forms of carp parvalbumin. Gut 2000 0.85
123 Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002 0.85
124 Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy 2006 0.85
125 Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression. Eur J Clin Invest 2008 0.84
126 Phenotypic and functional characterization of mast cells derived from renal tumor tissues. Exp Hematol 1998 0.84
127 Differential response of human basophils and mast cells to recombinant chemokines. Ann Hematol 1995 0.84
128 Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. Blood 1991 0.84
129 The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases. Int Arch Allergy Immunol 1998 0.84
130 The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999 0.84
131 Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor. J Biol Chem 1992 0.83
132 A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone. Leukemia 1996 0.83
133 Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001 0.83
134 Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. FASEB J 1999 0.83
135 Inhibition of stem cell factor dependent formation of human mast cells by interleukin-3 and interleukin-4. Int Arch Allergy Immunol 1994 0.83
136 Characterization of LDL and VLDL binding sites on human basophils and mast cells. Arterioscler Thromb Vasc Biol 1995 0.82
137 Human leukaemic stem cells: a novel target of therapy. Eur J Clin Invest 2004 0.82
138 FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest 2007 0.82
139 Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. J Allergy Clin Immunol 1996 0.82
140 CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol 2009 0.82
141 Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells. Int Arch Allergy Immunol 1993 0.82
142 Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Ann Hematol 1999 0.82
143 Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Leuk Lymphoma 1996 0.82
144 The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol 2006 0.81
145 A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE. J Allergy Clin Immunol 2001 0.81
146 Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol 1996 0.81
147 Expression of homing receptors and related molecules on human mast cells and basophils: a comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques. Tissue Antigens 1999 0.81
148 The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy 2014 0.81
149 Angiosarcoma of bone marrow with unusual expression of chymase: diagnosis in a trephine biopsy specimen. J Clin Pathol 2007 0.81
150 Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest 2009 0.81
151 Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. Life Sci 1996 0.81
152 Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990 0.81
153 Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and CD117/c-kit. J Immunol Methods 1995 0.81
154 Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest 2009 0.80
155 Immunophenotypic and functional characterization of human tonsillar mast cells. J Leukoc Biol 1997 0.80
156 Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patients. Int J Immunopathol Pharmacol 2008 0.80
157 Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens. Haematologica 2007 0.80
158 Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. Leuk Lymphoma 2003 0.80
159 Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition. J Immunol 1998 0.80
160 Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. Anticancer Res 2008 0.80
161 Numbers of colony-forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders. Eur J Clin Invest 2003 0.80
162 Dasatinib inhibits progenitor cell proliferation from polycythaemia vera. Eur J Clin Invest 2008 0.80
163 Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit ligand. Circulation 1995 0.80
164 Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol 1999 0.79
165 IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease. Eur J Immunol 2001 0.79
166 Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr Cancer Drug Targets 2009 0.79
167 Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction. Clin Exp Allergy 2014 0.79
168 "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol 2006 0.79
169 Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. Int Arch Allergy Immunol 1997 0.79
170 A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk Res 2001 0.79
171 Molecular and immunological characterization of a novel timothy grass (Phleum pratense) pollen allergen, Phl p 11. Clin Exp Allergy 2002 0.79
172 Detection of differentiation- and activation-linked cell surface antigens on cultured mast cell progenitors. Allergy 2005 0.79
173 Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis. Wien Klin Wochenschr 1998 0.79
174 Autoantibody reactivity in a case of Schnitzler's syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies. Int Arch Allergy Immunol 2000 0.78
175 Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 2001 0.78
176 Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem 1997 0.78
177 The Ash Wednesday bushfires in Victoria. Med J Aust 1984 0.78
178 In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Eur J Nucl Med 1996 0.78
179 A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells. Allergy 2008 0.78
180 Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens. J Allergy Clin Immunol 1993 0.78
181 Anaemia of the elderly (AOE): does it exist and does it matter in clinical practice? Eur J Clin Invest 2008 0.78
182 In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 1992 0.78
183 Stem cell factor-induced downregulation of c-kit in human lung mast cells and HMC-1 mast cells. Exp Hematol 1996 0.77
184 Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. Allergy 2013 0.77
185 Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates--synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood 1990 0.77
186 High-level expression in Escherichia coli and purification of recombinant plant profilins: comparison of IgE-binding capacity and allergenic activity. Biochem Biophys Res Commun 1996 0.77
187 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996 0.77
188 Fetuin in human bone marrow: detection in foetal tissue and patients with mastocytosis. Histochem J 2001 0.77
189 NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy 2012 0.77
190 Recombinant human interleukin 3 induces proliferation of inflammatory cells and keratinocytes in vivo. Lab Invest 1991 0.77
191 Human blood basophils synthesize interleukin-2 binding sites. Blood 1990 0.77
192 Evaluation of mast cell activation syndromes: impact of pathology and immunohistology. Int Arch Allergy Immunol 2012 0.77
193 Immunophenotypic characterization of human basophils and mast cells. Chem Immunol 1995 0.77
194 An in vitro model for the allergen-IgE-FcARI interaction. Int Arch Allergy Immunol 1999 0.77
195 Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010 0.77
196 Prognosis of patients with a second relapse of acute myeloid leukemia. Leukemia 2000 0.77
197 High level expression of birch pollen profilin (Bet v 2) in Escherichia coli: purification and characterization of the recombinant allergen. Biochem Biophys Res Commun 1995 0.77
198 Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Hum Pathol 1999 0.77
199 Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia. J Investig Med 1999 0.76
200 Does cord blood contain enough progenitor cells for transplantation? J Hematother 1994 0.76
201 Characterization of recombinant cat albumin. Clin Exp Allergy 2003 0.76
202 Recombinant allergens. Steps on the way to diagnosis and therapy of type I allergy. Adv Exp Med Biol 1996 0.76
203 Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. Int Arch Allergy Immunol 1997 0.76
204 New insights into the pathogenesis of the hyperimmunoglobulinaemia E syndrome. Eur J Clin Invest 2005 0.75
205 Recognition sites for microbes and components of the immune system on human mast cells: relationship to CD antigens and implications for host defense. Int J Immunopathol Pharmacol 2007 0.75
206 Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment. Allergy 2013 0.75
207 Thrombin augments vascular cell-dependent migration of human mast cells: role of MGF. Thromb Haemost 1997 0.75
208 Revealing the pathogenesis of the 5q- syndrome. Eur J Clin Invest 2008 0.75
209 Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991 0.75
210 Characterization of IgE-reactive autoantigens in atopic dermatitis. 1. Subcellular distribution and tissue-specific expression. Int Arch Allergy Immunol 1999 0.75
211 [Mastocytosis and eosinophilic leukemia: diagnostics and classification]. Pathologe 2012 0.75
212 Effects of vasoactive intestinal peptide (VIP) and somatostatin (SST) on lipoprotein receptor expression by A431 tumor cells. Life Sci 2001 0.75
213 Effects of dental amalgam and heavy metal cations on cytokine production by peripheral blood mononuclear cells in vitro. J Biomed Mater Res 1998 0.75
214 [New concepts in therapy of type I allergic diseases]. Wien Klin Wochenschr 1993 0.75
215 Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Ann Hematol 2013 0.75
216 Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. Cancer Genet Cytogenet 2001 0.75
217 Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). Wien Klin Wochenschr 1999 0.75
218 Resilience in child survivors of the Holocaust: toward the concept of resilience. Psychoanal Rev 1998 0.75
219 Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Invest 2001 0.75
220 Evaluation of neoplastic human mast cells by tryptase-immunoelectron microscopy. Histopathology 2006 0.75
221 Reciprocal translocation (3;5)(q26;q22) and possible BCHE gene involvement in an unusual myelogenous disorder with both myeloproliferative and dysplastic features. Cancer Genet Cytogenet 2000 0.75
222 Comorbidity, iron overload and HFE variants: a new prognostic complex in MDS? Eur J Clin Invest 2009 0.75
223 Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy Immunol 1999 0.75
224 Prisoners of war: long-term effects. Med J Aust 1981 0.75
225 Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 2007 0.75
226 Amplification of ribosomal RNA genes in acute myeloid leukemia. Genes Chromosomes Cancer 2001 0.75
227 Characterization of human prostate mast cells and their increase in periprostatic vein thrombosis. Am J Clin Pathol 2001 0.75
228 GM-CSF in combination with cytotoxic chemotherapy in AML patients. Bone Marrow Transplant 1990 0.75
229 Issues with dying patients. Med J Aust 1978 0.75
230 Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol 2000 0.75
231 Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J Nucl Med 1998 0.75
232 Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. Ann Hematol 2003 0.75
233 Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. Br J Haematol 1998 0.75
234 [Radioimmunometric determination of histamine in myeloproliferative syndromes]. Wien Klin Wochenschr 1989 0.75
235 Immunophenotypic analysis of HL-60 cells during basophilic differentiation. Int Arch Allergy Immunol 1996 0.75
236 [Effector cells in allergy: biological principles and new pharmacologic concepts]. Wien Klin Wochenschr 1993 0.75
237 Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. Hum Pathol 1997 0.75
238 Phorbol ester 12-O-tetradecanoylphorbol-13-acetate down-regulates expression of the c-kit proto-oncogene product. J Immunol 1993 0.75
239 Bone marrow mastocytosis associated with an undifferentiated extramedullary tumor of hemopoietic origin. Arch Pathol Lab Med 1997 0.75
240 [The use of highly polymorphic DNA systems in the demonstration of mixed chimerism following bone marrow transplantation]. Wien Klin Wochenschr 1991 0.75
241 Efficacy of standard treatment in patients with Hodgkin's disease--a single center experience. Wien Klin Wochenschr 2000 0.75
242 Immunophenotypic characterization of human bone marrow endosteal cells. Tissue Antigens 1999 0.75